Aditxt in asset purchase pact to acquire 50% of of Global Response Aid

Aditxt (ADTX) is pleased to announce the signing of an asset purchase agreement with Cellvera, that grants Aditxt , a 50% ownership in Global Response Aid FZE with the other 50% owned by global logistics leader Agility, . The consideration for the transaction is $24.5M , comprised of: the forgiveness of Aditxt’s $14.5M loan to Cellvera, and $10Min cash, and future royalties for 7 years. Together with Dr. Reddy’s Laboratories, Ltd. (RDY), GRA holds an exclusive, worldwide license for Avigan 200mg, excluding Japan, China and Russia. In connection with the closing of this transaction, the Share Exchange Agreement previously entered as of December 28, 2021, between Cellvera Global Holdings f/k/a AiPharma Global Holdings, and Aditxt and all other related agreements will be terminated. The closing of the transaction remains subject to a number of conditions, including but not limited to, among others, approval by Aditxt’s board of directors to enter into this transaction, financing of the purchase price, regulatory approvals for the transfer of shares, the resolution and satisfaction of all of Cellvera’s creditors inclusive of those creditors who have initiated claims, and securing the rights to additional 3rd-party IP assets. No assurance can be given that all of the conditions to closing will be obtained or satisfied, or that the transaction will ultimately close. "We believe this acquisition has the potential to help drive Aditxt’s strategic revenue and growth, as we move forward to help address a growing market need for more effective antivirals," said Amro Albanna, co-founder, chairman and CEO of Aditxt. "We are excited by the opportunity to play a key role in the development of Avigan in terms of clinical and commercial opportunities. We believe that Avigan can play a vital role in the treatment of a range of infectious diseases, due to the broad-spectrum nature of the molecule. Although we have only recently entered into the therapeutics market, our goal is to drive a paradigm shift in the treatment and prevention of infectious diseases globally through our newly formed subsidiary Adivir." GRA CEO Mitch Wilson said: "We’re very excited about the partnership with Aditxt. Aditxt knows how to assess, develop, and commercialize promising innovations with a focus on immune health. Its expertise is critical in helping GRA bring Avigan to its full potential."